Dual inhibition of BCL2L1 and MCL1 is highly effective against RET fusion-positive or MET exon 14 skipping mutation-positive lung adenocarcinoma cells-Reference-Cited by-同舟云学术

Dual inhibition of BCL2L1 and MCL1 is highly effective against RET fusion-positive or MET exon 14 skipping mutation-positive lung adenocarcinoma cells

Published:2022-11 Issue: Volume:630 Page:24-29
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Hirai Sachie^ORCID,Idogawa Masashi,Sumi Toshiyuki,Yamaguchi Miki,Niki Toshiro,Sakuma Yuji^ORCID

Funder

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference14 articles.

1. MET exon 14 skipping mutations in non-small-cell lung cancer: an overview of biology, clinical outcomes, and testing considerations;Socinski;JCO Precis Oncol,2021

2. Patritumab deruxtecan: paving the way for EGFR-TKI-resistant NSCLC;Lim;Cancer Discov,2022

3. Anthrax toxin receptor 2 is a potential therapeutic target for non-small cell lung carcinoma with MET exon 14 skipping mutations;Yamaguchi;Exp Cell Res,2022

4. MCL1 inhibition enhances the therapeutic effect of MEK inhibitors in KRAS-mutant lung adenocarcinoma cells;Tada;Lung Cancer,2019

5. EGFR-independent EGFR-mutant lung adenocarcinoma cells depend on Bcl-xL and MCL1 for survival;Hirai;Biochem Biophys Res Commun,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Junctional adhesion molecule 3 is a potential therapeutic target for small cell lung carcinoma;Experimental Cell Research;2023-05

2. A novel anoikis-related gene signature to predict the prognosis, immune infiltration, and therapeutic outcome of lung adenocarcinoma;Journal of Thoracic Disease;2023-03